Effect of interleukin-18 on metastasis of mouse osteosarcoma cells

Cancer Immunology, Immunotherapy

Volumn 55, Issue 9, 2006, Pages 1151-1158

  Nakamura, Yoshiteru ^a   Yamada, Naoko ^a   Ohyama, Hideki ^a   Nakasho, Keiji ^a   Nishizawa, Yasuko ^b   Okamoto, Takuya ^a   Futani, Hiroyuki ^a   Yoshiya, Shinichi ^a   Okamura, Haruki ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Interleukin 18; Metastasis; Migration; Osteosarcoma

Indexed keywords

ANTIBODY; GANGLIOSIDE GM1 ANTIBODY; INTERLEUKIN 18; INTERLEUKIN 18 BETA RECEPTOR; INTERLEUKIN 18 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL STRAIN LM8; CONTROLLED STUDY; DRUG EFFECT; HOST CELL; IMMUNOPHARMACOLOGY; LIVER METASTASIS; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; DRUG SCREENING ASSAYS, ANTITUMOR; IMMUNOTHERAPY; INTERLEUKIN-18; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; OSTEOSARCOMA;

EID: 33744498623     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0097-3     Document Type: Article

References (30)

1. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, Mori S, Yoshikawa H (1998) Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 76:418-422
2. Cao R, Farnebo J, Kurimoto M, Cao Y (1999) Interleukin-18 acts as angiogenesis and tumor suppressor. FASEB J 13:2195-2202
3. Carrascal MT, Mendoza L, Valcarcel M, Salado C, Egilegor E, Telleria N, Vidal-Vanaclocha F, Dinarello CA (2003) Interleukin-18 binding protein reduces B16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 63:491-497
4. Giancotti FG, Ruoslahti E (1990) Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 60:849-859
5. Glasgow LA, Kern ER (1981) Effect of interferon administration on pulmonary osteogenic sarcomas in an experimental murine model. J Natl Cancer Inst 67:207-212
6. Good CR, O'Keefe RJ, Puzas JE, Schwarz EM, Rosier RN (2002) Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors. J Surg Oncol 79:174-179
7. Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19:18-54
8. Gunel N, Coskun U, Sancak B, Hasdemir O, Sare M, Bayram O, Celenkoglu G, Ozkan S (2003) Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage. Am J Clin Oncol 26:416-421
9. Hosohara K, Ueda H, Kashiwamura S, Yano T, Ogura T, Marukawa S, Okamura H (2002) Interleukin-18 induces acute biphasic reduction in the levels of circulating leukocytes in mice. Clin Diagn Lab Immunol 9:777-783
10. Huvos A (1991) Bone tumors: diagnostic treatment, and prognosis. W.B. Saunders, Philadelphia, PA
11. Iwasaki T, Yamashita K, Tsujimura T, Kashiwamura S, Tsutsui H, Kaisho T, Sugihara A, Yamada N, Mukai M, Yoneda T, Okamura H, Akedo H, Terada N (2002) Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunother 25:S52-S60
12. Jakub G (2000) Interleukin 18-interferon-γ inducing factor - a novel player in tumor immunotherapy. Cytokine 12:332-338
13. Jeffree GM, Price CH, Sissons HA (1975) The metastatic patterns of osteosarcoma. Cancer 32:87-107
14. Jiang D, Ying W, Lu Y, Wan J, Zhai Y, Liu W, Zhu Y, Qiu Z, Qian X, He F (2003) Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 3:724-737
15. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, Hiraide H, Mochizuki H (2001) Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 92:2050-2055
16. Kuhara T, Iigo M, Itoh T, Ushida Y, Sekine K, Terada N, Okamura H, Tsuda H (2000) Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr Cancer 38:192-199
17. Lebel-Binay S, Berger A, Zinzindohoue F, Cugnenc P-H, Thiounn N, Fridman WH, Pages F (2000) Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 11:15-26
18. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G (1992) Chemotherapy for non metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10:5-15
19. Miyamoto N, Higuchi Y, Mori K, Ito M, Tsurudome M, Nishio M, Yamada H, Sudo A, Kato K, Uchida A, Ito Y (2002) Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2:25-38
20. Morel JCM, Park CC, Woods JM, Koch AE (2001) A novel role for interleukin-18 in adhesion molecule induction through NF kappa B and phosphatidylinositol (PI) 3-kinase-dependent signal transduction pathways. J Biol Chem 276:37069-37075
21. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K, Uchida A (1995) Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 61:148-152
22. Nakata A, Tsujimura T, Sugihara A, Okamura H, Iwasaki T, Shinkai K, Iwata N, Kakishita E, Akedo H, Terada N (1999) Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res 19:4131-4138
23. Ogura T, Ueda H, Hosohara K, Tsuji R, Nagata Y, Kashiwamura S, Okamura H (2001) Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood 98:2101-2107
24. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M (1997) Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17:3253-3258
25. Okamoto T, Yamada N, Tsujimura T, Sugihara A, Nishizawa Y, Ueda H, Kashiwamura S, Tsutsui H, Futani H, Maruo S, Okamura H, Terada N (2004) Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells. J Interferon Cytokine Res 24:161-167
26. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K (1998) A novel cytokine that augment both innate and aquired immunity. Adv Immunol 70:281-312
27. Pratt CB, Champion JE, Fleming ID, Rao B, Kumar APM, Evans WE, Green AA, George S (1990) Adjuvant chemotherapy for osteosarcoma of the extremity; Long-term results of two consecutive prospective protocol studies. Cancer 65:439-445
28. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP (1995) Systemic relapse of patients with osteogenic sarcoma; Prognostic factors for long term survival. Cancer 75:1084-1093
29. G-nitro-L-arginine and/or L-arginine on experimental pulmonary metastasis in mice. Cancer Lett 87:115-120
30. Yamashita K, Iwasaki T, Tsujimura T, Sugihara A, Yamada N, Ueda H, Okamura H, Futani H, Maruo S, Terada N (2002) Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow. Oncol Rep 9:1237-1244